Biomarkers of Endometrial Receptivity (NCT04619524) | Clinical Trial Compass
RecruitingNot Applicable
Biomarkers of Endometrial Receptivity
Czechia476 participantsStarted 2018-05-01
Plain-language summary
Analysis of proteins from cervical mucus will be done in patients undergoing infertility treatment (fresh or frozen embryo transfer). Cervical mucus will be analysed for potential new biomarkers of endometrium receptivity. Comparison of the peptide spectrum will be done for the pregnant and not pregnant patients.
Who can participate
Age range
36 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria - Arm A - stimulated cycle:
* female aged less than 37 years (maximally 36y + 364d)
* no smoker
* normal menstrual cycles lasting between 25 to 35 days
* had been infertile for less than five years
* normal responder
* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF/ intracytoplasmic sperm injection (ICSI) embryo transfer cycles and/or frozen-thawed embryo transfer cycles
* sperm obtained through ejaculation
* spermiogram more than 5 million sperm/mL
* BMI 19-29 kg/m2
* follicle stimulating hormone (FSH) \< 10 IU/L on the third day
* basal antral follicle count of 5-15
* undergoing the same routine gonadotrophin-releasing hormone agonist (GnRHa) long depot or gonadotrophin-releasing hormone antagonist (GnRH-ant.) protocol
* informed consent
Exclusion Criteria - Arm A - stimulated cycle:
* genetic disease
* metabolic and/or endocrine disorders
* polycystic ovary syndrome (defined by the Rotterdam criteria)
* women with prior diagnosis of endometriosis or adenomyosis
* previous gynecological/pelvic surgery except for salpingectomy
* repeated spontaneous abortions (two or more)
* previously less than 5 oocytes and/or serum anti-Mullerian hormone value \< 1.0 mIU/ml or more than 20 oocytes, milli-International unit (mIU)
* previous ovarian hyperstimulation syndrome (OHSS)
* presence of any structural abnormality of the reproductive system
* donor oocyte cycles
* severe male factor infertility \< 5 million sperm/mL
* low…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Mass spectrometer analysis of the proteins from cervical mucus
Timeframe: 48 months
Trial details
NCT IDNCT04619524
SponsorThe Institute of Molecular and Translational Medicine, Czech Republic